{
    "clinical_study": {
        "@rank": "80701", 
        "brief_summary": {
            "textblock": "This is a single center, single arm, open-label phase II study to determine the efficacy and\n      safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors\n      expressing tandem TCR and 4-1BB (TCR/4-1BB) co-stimulatory domains (referred to as CART-19\n      cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.\n      Inclusion criteria are designed to include adult patients aged greater than 18 with B cell\n      ALL, relapsed or refractory, with no available curative treatment options (such as\n      autologous or allogeneic stem cell transplantation) who have limited prognosis (greater than\n      12 weeks survival expectancy) with currently available therapies. The study product is\n      CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB\n      administered by a single i.v. infusion of 1 to 5 x 108 transduced CAR T cells."
        }, 
        "brief_title": "PHASE II STUDY OF REDIRECTED AUTOLOGOUS T CELLS ENGINEERED TO CONTAIN ANTI-CD19 ATTACHED TO TCR AND 4-1BB SIGNALING DOMAINS IN PATIENTS WITH CHEMOTHERAPY RESISTANT OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Patients With B Cell ALL, Relapsed or Refractory, With no Available", 
            "Curative Treatment Options (Such as Autologous or Allogeneic Stem Cell", 
            "Transplantation) Who Have Limited Prognosis (> 12 Weeks Survival Expectancy)", 
            "With Currently Available Therapies."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent form must be obtained prior to any study procedure\n\n          -  Relapsed orrefractory B-cell ALL a. 1st or greater BM relapse OR b. Any marrow\n             relapse after allogeneic HSCT and 100 days from transplant OR c. For patients with\n             refractory disease: i. less than 60 years old that have not achieved a CR after\n             greater tjam 2 or more chemotherapy regimens ii. greater than or equal to 60 years\n             old that have not achieved a CR after 1 prior chemotherapy regimen d. Patients with\n             Ph+ ALL are eligible if they have failed tyrosine kinase inhibitor therapy\n\n        Adequate organ function defined as:\n\n        a. Creatinine less than or equal to 1.6 mg/dl b. ALT/AST less than or equal to 3x upper\n        limit of normal range c. Direct bilirubin less than or equal to 2.0 mg/dl d. Must have a\n        minimum level of pulmonary reserve defined as less than or equal to Grade 1 dyspnea and\n        pulse oxygen greater than 92% on room air e. Left Ventricle Ejection Fraction (LVEF)\n        greater than or equal to 40% confirmed by ECHO/MUGA 4.\n\n        Bone marrow with greater than or equal to 5% lymphoblasts\n\n          -  Life expectancy greater than 12 weeks\n\n          -  Male or female age greater than or equal to 18 years\n\n          -  A ECOG Performance Status that is either 0 or 1 .-No contraindications for\n             leukapheres\n\n        Exclusion Criteria:\n\n          -  Isolated extra-medullary disease relapse\n\n          -  Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi\n             anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure\n             syndrome\n\n          -  Uncontrolled active hepatitis B or active hepatitis C\n\n          -  HIV infection\n\n          -  Active acute or chronic graft-versus-host disease (GVHD)\n\n          -  Concurrent use of systemic steroids or immunosuppressant medications\n\n          -  Active CNS involvement by malignancy. Note: Patients with history of CNS disease that\n             has been effectively treated will be eligible provided that treatment was 4 weeks\n             before enrollment\n\n          -  Pregnant or nursing (lactating) women, female study participants of reproductive\n             potential must have a negative serum or urine pregnancy test within 48 hours before\n             infusion\n\n          -  Participation in a prior investigational study within 4 weeks prior to enrollment or\n             longer if required by local regulation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "id_info": {
            "nct_id": "NCT02030847", 
            "org_study_id": "UPCC 21413"
        }, 
        "intervention": {
            "description": "CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 108 transduced CAR T cells", 
            "intervention_name": "CART-19 cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Noelle Frey, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Noelle Frey, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "PHASE II STUDY OF REDIRECTED AUTOLOGOUS T CELLS ENGINEERED TO CONTAIN ANTI-CD19 ATTACHED TO TCR AND 4-1BB SIGNALING DOMAINS IN PATIENTS WITH CHEMOTHERAPY RESISTANT OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Noelle Frey, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Noelle Frey, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030847"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}